244 related articles for article (PubMed ID: 28692028)
21. Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A; Lestang E; Guillaume T; Delaunay J; Ayari S; Blin N; Clavert A; Tessoulin B; Dubruille V; Mahe B; Roland V; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Chevallier P
Eur J Haematol; 2013 Mar; 90(3):177-86. PubMed ID: 23301689
[TBL] [Abstract][Full Text] [Related]
22. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma.
Kawamura K; Tsukada N; Kanda Y; Ikeda T; Yoshida A; Ueda Y; Ishida T; Suzuki K; Murakami H
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1392-1398. PubMed ID: 29555314
[TBL] [Abstract][Full Text] [Related]
23. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study.
Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A;
Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922
[TBL] [Abstract][Full Text] [Related]
24. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.
Montefusco V; Mussetti A; Rezzonico F; Maura F; Pennisi M; de Philippis C; Capecchi M; Corradini P
Bone Marrow Transplant; 2017 Dec; 52(12):1602-1608. PubMed ID: 28892086
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
27. The allogeneic dilemma.
Harousseau JL
Bone Marrow Transplant; 2007 Dec; 40(12):1123-8. PubMed ID: 17680016
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.
Rasche L; Röllig C; Stuhler G; Danhof S; Mielke S; Grigoleit GU; Dissen L; Schemmel L; Middeke JM; Rücker V; Schreder M; Schetelig J; Bornhäuser M; Einsele H; Thiede C; Knop S
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1988-1996. PubMed ID: 27590108
[TBL] [Abstract][Full Text] [Related]
29. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
30. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Lokhorst HM; Segeren CM; Verdonck LF; van der Holt B; Raymakers R; van Oers MH; Barge RM; Schouten HC; Westveer PH; Steijaert MM; Cornelissen JJ; Sonneveld P;
J Clin Oncol; 2003 May; 21(9):1728-33. PubMed ID: 12721248
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic stem cell transplantation and targeted immunotherapy for multiple myeloma.
Danylesko I; Shimoni A; Nagler A
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S330-48. PubMed ID: 24290219
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
[TBL] [Abstract][Full Text] [Related]
33. Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation.
Auner HW; Szydlo R; van Biezen A; Iacobelli S; Gahrton G; Milpied N; Volin L; Janssen J; Nguyen Quoc S; Michallet M; Schoemans H; El Cheikh J; Petersen E; Guilhot F; Schönland S; Ahlberg L; Morris C; Garderet L; de Witte T; Kröger N;
Bone Marrow Transplant; 2013 Nov; 48(11):1395-400. PubMed ID: 23708704
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
35. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
[TBL] [Abstract][Full Text] [Related]
36. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
Santoro N; Ruggeri A; Labopin M; Bacigalupo A; Ciceri F; Gülbaş Z; Huang H; Afanasyev B; Arcese W; Wu D; Koc Y; Tischer J; Santarone S; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2017 May; 10(1):113. PubMed ID: 28558762
[TBL] [Abstract][Full Text] [Related]
37. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies.
Leng S; Moshier E; Tremblay D; Hu L; Biran N; Barman N; Parekh S; Cho H; Madduri D; Richter J; Barlogie B; Jagannath S; Chari A
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e734-e751. PubMed ID: 32660906
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017.
Yin X; Tang L; Fan F; Jiang Q; Sun C; Hu Y
Cancer Cell Int; 2018; 18():62. PubMed ID: 29713245
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience.
Minnema MC; van Dorp S; van de Donk NW; Schouten F; Kersten MJ; Coenen JL; Schouten H; Zweegman S; Schaafsma R; Lokhorst HM
Bone Marrow Transplant; 2011 Feb; 46(2):244-9. PubMed ID: 20400982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
